Skip to main content

Table 4 Total body weight gain by obesity class and CYP phenotype in participants prescribed with citalopram, paroxetine, fluoxetine, and sertraline

From: Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

Normal and Underweight Group

CYP2C19

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Citalopram

TBWG 6 mths, %

n = 17

4.4 (95% CI 1.9 – 6.8)

n = 26

1.5 (95% CI -0.3 – 3.4)

n = 18

1.5 (95% CI -0.6 – 3.5)

0.11

Sertraline

TBWG 6 mths, %

n = 12

2.6 (95% CI 0.9 – 4.5)

n = 28

1.2 (95% CI -0.8 – 3.1)

n = 19

2.7 (95% CI 1.1 – 4.3)

0.32

CYP2D6

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Paroxetine

TBWG 6 mths, %

n = 33

0.6 (95% CI -0.7 – 1.9)

n = 11

0.4 (95% CI -2.7 – 3.6)

n = 1

3.0

0.65

Sertraline

TBWG 6 mths, %

n = 49

1.8 (95% CI 0.6 – 3.1)

n = 8

1.4 (95% CI -0.5 – 3.4)

n = 2

6.7 (95% CI -55.1 – 69.6)

0.16

Fluoxetine

TBWG 6 mths, %

n = 32

1.2 (95% CI -0.3 – 2.7)

n = 14

0.9 (95% CI -1.8 – 3.6)

 

0.88

CYP2C9

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Fluoxetine

TBWG 6 mths, %

n = 26

1.9 (95% CI -0.3 – 4.1)

n = 20

0.5 (95% CI -1.1 – 2.1)

 

0.60

Overweight Group

CYP2C19

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Citalopram

TBWG 6 mths, %

n = 21

3.0 (95% CI -0.3 – 6.4)

n = 34

-0.3 (95% CI -2.1 – 1.5)

n = 24

1.3 (95% CI -3.6 – 1.1)

0.02

Sertraline

TBWG 6 mths, %

n = 19

1.5 (95% CI -0.2 – 3.1)

n = 17

0.7 (95% CI -0.7 – 2.1)

n = 14

2.3 (95% CI 0.6 – 4.1)

0.44

CYP2D6

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Paroxetine

TBWG 6 mths, %

n = 12

1.6 (95% CI -0.8 – 3.9)

n = 12

3.5 (95% CI 1.4 – 5.6)

n = 1

1.3

0.13

Sertraline

TBWG 6 mths, %

n = 40

1.3 (95% CI 0.3 – 2.3)

n = 8

2.3 (95% CI -0.5 – 3.4)

n = 2

0.9 (95% CI -25.0 – 26.8)

0.69

Fluoxetine

TBWG 6 mths, %

n = 28

1.2 (95% CI -2.9 – 0.4)

n = 20

0.5 (95% CI -2.2 – 3.2)

 

0.21

CYP2C9

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Fluoxetine

TBWG 6 mths, %

n = 16

0.6 (95% CI -3.3 – 2.1)

n = 32

0.5 (95% CI -2.3 – 1.3)

 

0.91

Obesity Group

CYP2C19

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Citalopram

TBWG 6 mths, %

n = 20

0.8 (95% CI -0.5 – 1.9)

n = 23

0.4 (95% CI -0.8 – 1.7)

n = 19

-0.3 (95% CI -2.7 – 2.2)

0.18

Sertraline

TBWG 6 mths, %

n = 15

-0.9 (95% CI -3.1 – 1.2)

n = 21

-0.7 (95% CI -2.6 – 1.2)

n = 18

0.6 (95% CI -1.7 – 2.9)

0.52

CYP2D6

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Paroxetine

TBWG 6 mths, %

n = 11

0.4 (95% CI -0.8 – 1.6)

n = 25

0.7 (95% CI -1.3 – 2.6)

n = 1

0.4

0.98

Sertraline

TBWG 6 mths, %

n = 38

0.1 (95% CI -1.6 – 1.3)

n = 15

0.3 (95% CI -1.8 – 1.2)

n = 1

-10.6

0.26

Fluoxetine

TBWG 6 mths, %

n = 19

0.1 (95% CI -0.9 – 1.0)

n = 76

-0.9 (95% CI -3.1 – 1.2)

n = 2

1.3 (95% CI -33.0 – 35.6)

0.79

CYP2C9

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p-value

Fluoxetine

TBWG 6 mths, %

n = 34

0.2 (95% CI -1.1 – 1.5)

n = 63

-0.3 (95% CI -1.5 – 0.8)

 

0.30

  1. Continuous data are summarized as mean (95% CI)
  2. Abbreviations used: CI confidence interval, TBWG Total Body Weight Gain
  3. p-value: calculated with ANCOVA with metabolizer status and BMI as covariate
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us